Quince Therapeutics (QNCX) Stock Price, News & Analysis

Company Overview

Quince Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company is advancing therapies designed to address underlying disease mechanisms and improve outcomes for patients with serious genetic and neurological disorders.

Quince’s lead program is based on the EryDex drug-delivery platform, which uses a patient’s own red blood cells to encapsulate and gradually release a corticosteroid in the body. The company is evaluating this approach for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological impairment, immune-system dysfunction and other serious complications.

The company’s operations are centered on the development of its investigational therapies and related clinical programs, with research and clinical activities conducted through collaborations and studies serving patients in relevant international markets. Quince Therapeutics was formed through the evolution of Cortexyme, Inc., following the company’s acquisition of EryDel and a subsequent strategic shift toward rare-disease therapeutics.

Quince Therapeutics is headquartered in San Francisco, California, and its shares trade on the Nasdaq under the symbol QNCX. The company’s leadership and scientific teams focus on advancing its clinical pipeline, regulatory strategy and drug-delivery technology toward potential commercialization.

Key Stats

• Today's Range: $31.73 to $31.73
• 50-Day Range: $26.72 to $32.01
• 52-Week Range: $15.10 to $909.98
• Volume: N/A
• Average Volume: 31,090 shs
• Market Capitalization: $32.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $189.88
• Consensus Rating: Moderate Buy

Quince Therapeutics Stock Analysis - MarketRank™

Quince Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 614th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quince Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 2 strong buy ratings, 7 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Quince Therapeutics has a consensus price target of $189.88, representing about 498.4% upside from its current price of $31.73.

Amount of Analyst Coverage

Quince Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quince Therapeutics are expected to grow in the coming year, from ($8.39) to ($3.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.24% of the float of Quince Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Quince Therapeutics has a short interest ratio ("days to cover") of 2.67, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quince Therapeutics has recently increased by 19.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quince Therapeutics does not currently pay a dividend.

Dividend Growth

Quince Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quince Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.60% of the stock of Quince Therapeutics is held by insiders.

Percentage Held by Institutions

30.75% of the stock of Quince Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QNCX
• Previous Symbol: NASDAQ:CRTX
• CIK: 1662774
• Web: www.quincetx.com
• Phone: (415) 910-5717
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quince Therapeutics: $189.88
• High Price Target: $1,000.00
• Low Price Target: $68.00
• Potential Upside/Downside: +498.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($156.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -133.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.52
• Quick Ratio: 14.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($128.18) per share
• Price / Book: -0.25

Miscellaneous

• Outstanding Shares: 1,017,000
• Free Float: 960,000
• Market Cap: $32.27 million
• Optionable: No Data
• Beta: 1.33